During the 42-month entire study period ( including the study treatment and follow-up periods ) , the composite outcome occurred in 33 patients ( 20.8 % ) in the warfarin group and in 42 ( 24.0 % ) in the placebo group ( HR , 0.75 ; 95 % CI , 0.47-1 .18 ) .